Clinical Trial Update: Phase I/II Study of SENL103 for Relapsed or Refractory Multiple Myeloma: A Multicenter, Open-Label, Single-Arm Trial. [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II study of SENL103 for relapsed or refractory multiple myeloma is listed as not yet recruiting, representing an early-stage, non-enrolling trial.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• SENL103

Snippet

Sponsor: Hebei Senlang Biotechnology Inc., Ltd. | Conditions: Multiple Myeloma in Relapse, Multiple Myeloma Refractory | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING